Strong

Sono-Tek Announces Preliminary Net Sales for Q4 and FY2024 and Provides Preliminary Sales Guidance for Q1 FY2025 and FY2025

Retrieved on: 
Monday, April 8, 2024
YOY, COVID-19, Growth, Strong

MILTON, N.Y., April 08, 2024 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced preliminary net sales and backlog for the fourth quarter of fiscal year 2024, ended February 29, 2024, and for the full fiscal year.

Key Points: 
  • Preliminary net sales for the fourth quarter of FY2024 were approximately $4.8 million, compared to net sales of $3.7 million for the fourth quarter a year ago, an increase of approximately 30%.
  • Preliminary net sales for the twelve months of FY2024, were approximately $19.7 million, an increase of approximately 31% from net sales of $15.1 million in FY2023.
  • Net sales for the first quarter of FY2025, ending May 31, 2024, are expected to increase approximately 35%-40% year-over-year, compared to a weaker supply chain constrained period in last year’s first quarter.
  • Record shipments drove the increase, reflecting robust orders and delivery of several large orders which were delayed by Covid-related supply chain issues of the previous year.

AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Fabry disease, PD, GCS, Drug development, Strong, Risk, Doctor of Philosophy, Safety, Therapy, Pharmacology, Pharmacokinetics, CNS, American College, Development, Patient, Pharmaceutical industry

AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.
  • “These results highlight the transformative potential of AL01211 as a best-in-class GCS inhibitor,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.
  • “Our Phase 1 study provided the critical safety and biomarker data to support our ongoing Phase 2 clinical trial in patients with Fabry Disease.
  • “In our trial, AL01211 demonstrated dose-dependent PK and PD effects with a clear correlation between AL01211 exposure and reduction in disease biomarkers.

KBRA Releases Research – Synthetic Risk Transfers Taking the Spotlight

Retrieved on: 
Tuesday, February 20, 2024
Banking, Professional Services, Finance, Strong, KBRA, Basel III, SRT, Research, Bank

KBRA releases research that examines synthetic risk transfer (SRT) transactions.

Key Points: 
  • KBRA releases research that examines synthetic risk transfer (SRT) transactions.
  • Dialogue with market participants regarding SRTs has increased ahead of upcoming Basel 3 regulations set to take effect in mid-2025.
  • The regulations will substantially change how risk-weighted assets are calculated, resulting in rising capital charges for various portfolio assets.
  • KBRA has rated several SRT transactions, with market conditions suggesting a significant pickup in the use of these structures going forward.

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

Nine Mile Metals Mobilizes California Lake VMS Drill Program and Introduces New Targeting Technology, Bathurst Mining Camp, New Brunswick

Retrieved on: 
Thursday, November 16, 2023
FSE, BMC, NB, Strong, CSE, OTCQB, N.B, Geology, VMS, Algorithm, Chapais, Magnetotellurics, Brunswick 12 mine, Bathurst Mining Camp, Reindeer, Acoustic, KQ9, EEX, Outline, Lens

ESSCO identified the sub surface 3D density targets consistent with existing Bathurst Mining Camp VMS deposits as baseline models for their technology processes.

Key Points: 
  • ESSCO identified the sub surface 3D density targets consistent with existing Bathurst Mining Camp VMS deposits as baseline models for their technology processes.
  • This technology was developed as a regional screening tool to facilitate targeting within large, known productive mineralized camps such as the Bathurst Mining Camp (“BMC”).
  • Our recent land acquisitions have made it possible to finalize our technology targeting process on our entire Nine Mile Metals portfolio.
  • Chapais also integrates Starlink Satellite Internet technology at their rig providing instant drill hole monitoring and metrics in real time.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Principal, Ruijin Hospital, Fabry disease, Enzyme replacement therapy, GCS, Pharmacokinetics, Strong, Nephrology, Safety, Therapy, Patient, Pharmaceutical industry

AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.

Key Points: 
  • AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
  • AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed to treat glycosphingolipid storage diseases, including Fabry Disease and Type 1 Gaucher Disease.
  • “We are delighted to initiate enrollment in our Phase 2 study for patients with Fabry disease at one of the most renowned academic centers in China,” said Dr. Pedro Huertas, M.D.
  • I am excited to have dosed the first patient in the company’s Phase 2 program for AL01211 and am dedicated to maintaining the highest standards throughout the trial.”

AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, PK, PD, IV, Aes, Clinical trial, Fabry disease, Pharmacokinetics, Quality of life, Ruijin Hospital, Nephrology, Trust, Patient, CDE, National Medical Products Administration, GCS, Principal, Center for Drug Evaluation and Research, Therapy, Strong, IND, NMPA, Safety, Pharmaceutical industry, Fabry

AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.

Key Points: 
  • AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
  • AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease.
  • It has completed a phase 1 clinical trial in healthy volunteers in Australia and a bridging phase 1 trial in China under IND approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
  • With this in mind, we are truly excited about our participation in this trial, as we strive to improve the daily lives of patients with Fabry disease.”

AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease

Retrieved on: 
Wednesday, June 21, 2023
Health, FDA, General Health, Clinical Trials, Research, Science, Pharmaceutical, Male, Fabry disease, Quality of life, Plasma, ERT, Patient, GCS, Enzyme replacement therapy, Therapy, Strong, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry

“FDA clearance for AL1211 marks an important clinical milestone for AceLink,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.

Key Points: 
  • “FDA clearance for AL1211 marks an important clinical milestone for AceLink,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.
  • Phase 1 clinical trials evaluated both single ascending dosing and multiple ascending dosing.
  • AL1211 was orally administered to healthy volunteers as a single dose up to 60 mg or multiple doses of up to 30 mg once daily for 14 days.
  • Globotriasosylceramide (Gb3), the disease-causing lipid of Fabry Disease, was also significantly reduced.

The National Anti-Corruption Commission Thailand (NACC) collaborates with Bangkok to combat and reduce corruption in 50 Bangkok’s districts through a strong community project

Retrieved on: 
Thursday, June 1, 2023
News, Ministry of Finance, Private sector, Risk, Tantalum carbide, STRONG, Comptroller, Integration, Bureau, Policy, Bangkok Metropolitan Administration, Strong, Public, NACC, Quality of life, Finance, Government, Virtue, Social change, Implementation, Ministry, Development, Guideline, National Anti-Corruption Commission (Thailand), Sufficiency economy, Ethics, Community development, Fraud, Legislation, Management, Security (finance), Corruption

"Strong Community Project for Self-Development in accordance with the Sufficiency Economy Philosophy 2023" is a part of Bangkok's developing city policy.

Key Points: 
  • "Strong Community Project for Self-Development in accordance with the Sufficiency Economy Philosophy 2023" is a part of Bangkok's developing city policy.
  • Bangkok has a policy to develop the community to be a livable city by using new management principles.
  • It supports the development of quality of life and community to be strong and self-sufficient.
  • The activities were attended by 2,014 community representatives from the Bangkok area via an electronic meeting (Zoom Webinar).